Last update: Jan. 15, 2019
Not risky for breastfeeding or infant.
An antihypertensive agent indicated in severe arterial hypertension.
Oral administration of 5 to 40mg daily in one or two doses, with the possibility of reaching 100mg daily.
Low doses of oral Minoxidil, from 0.5 to 2.5 mg daily, are being used to treat alopecia in women (Sinclair 2018, Perera 2017).
It is excreted in breastmilk in clinically insignificant amounts and no problems have been observed in an infant whose mother was taking it at an antihypertensive dose of 7.5 to 10 mg per day (Valdivieso 1985). The highest relative dose (RD) (5%) was obtained at the time of taking the medication, decreasing RD at three hours to 1.2%, at six hours to 0.3% and at nine hours to 0.1%.
You can therefore minimize the risk by avoiding breastfeeding at the time of taking the medication, which is when the levels in milk are higher.
The low doses that are prescribed for the treatment of alopecia pose few problems for breastfeeding.
American Academy of Pediatrics: it is a medication which is usually compatible with breastfeeding (Malachias 2016, AAP 2001). Some authors consider it safe in the case of breastfeeding older infants (Anderson 2018).
There are no published reports with antihypertensive doses greater than 10 mg per day, so in these cases, safer known alternatives may be preferable, especially in the neonatal period and in case of prematurity (Anderson 2018).
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine from United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM